Is Tirzepatide the New Game Changer in Type 2 Diabetes?
<b>Background:</b> Tirzepatide (TZP) is a once-weekly glucagon-like peptide 1 (GLP-1) and glucose-dependent-insulinotropic-polypeptide (GIP) receptor co-agonist approved for T2D. TZP provides promising evidence in improving glucose control and weight loss in T2D and obesity across preclinical and hu...
Guardat en:
| Autors principals: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2024-02-01
|
| Col·lecció: | Endocrines |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/2673-396X/5/1/5 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
